Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression

Devora Champa, Marika A Russo, Xiao-Hui Liao, Samuel Refetoff, Ronald A Ghossein, and Antonio Di Cristofano

Abstract

Poorly differentiated tumors of the thyroid gland (PDTC) are generally characterized by a poor prognosis due to their resistance to available therapeutic approaches. The relative rarity of these tumors is a major obstacle to our understanding of the molecular mechanisms leading to tumor aggressiveness and drug resistance, and consequently to the development of novel therapies. By simultaneously activating Kras and deleting p53 (Trp53) in thyroid follicular cells, we have generated a novel mouse model that develops papillary thyroid cancer invariably progressing to PDTC. In several cases, tumors further progress to anaplastic carcinomas. The poorly differentiated tumors are morphologically and functionally similar to their human counterparts and depend on MEK/ERK signaling for proliferation. Using primary carcinomas as well as carcinoma-derived cell lines, we also demonstrate that these tumors are intrinsically resistant to apoptosis due to high levels of expression of the Bcl2 family members, Bcl2a1 and Mcl1, and can be effectively targeted by Obatoclax, a small-molecule pan-inhibitor of the Bcl2 family. Furthermore, we show that Bcl2 family inhibition synergizes with MEK inhibition as well as with doxorubicin in inducing cell death. Thus, our studies in a novel, relevant mouse model have uncovered a promising druggable feature of aggressive thyroid cancers.

Key Words

- thyroid cancer
- mouse model
- cell death

Introduction

Thyroid cancer is the fifth most prevalent cancer in women, with over 45,000 new cases estimated for 2013 (Siegel et al. 2013). Although the vast majority of these tumors are effectively managed by surgical resection followed by radioactive iodine therapy (American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer et al. 2009), a subset of lesions, which includes recurring well-differentiated, poorly differentiated, and anaplastic tumors, is refractory to current therapeutic approaches, behaves aggressively, is almost invariably fatal, and thus represents a critical clinical issue (Siironen et al. 2010, Ibrahimpasic et al. 2013).
Poorly differentiated thyroid tumors have been recently recognized as a defined, although quite heterogeneous, clinical entity, characterized by the presence of a solid, trabecular, or insular growth pattern, absence of conventional nuclear features of papillary carcinoma, and the presence of at least one of the following features: convoluted nuclei, high mitotic activity, or tumor necrosis (Volante et al. 2007).

Genetic lesions associated with aggressive poorly differentiated tumors include activation of RAS isoforms and inactivation of p53 (TRP53) (Nikiforov 2004) and, with a lower frequency, activation of BRAF or presence of the RET/PTC rearrangement (Ricarte-Filho et al. 2009). Among the RAS isoforms, NRAS represents the most commonly mutated gene (Volante et al. 2009), although in a different series KRAS was found to be mutated in approximately 45% of all PDTCs analyzed (Garcia-Rostan et al. 2003).

Based on these data, we have generated a compound mouse model carrying a constitutively active allele of Kras (G12D) and a null p53 allele. The use of a human thyroid peroxidase promoter-driven Cre recombinase restricts the functionality of the engineered alleles to the thyroid epithelial cells. We show that double-mutant mice invariably develop PDTC in a background of papillary thyroid cancer and that these tumors phenocopy human PDTC and its aggressive behavior. Furthermore, we identify Bcl2a1 (Bcl2a1a) and Mcl1 as viable therapeutic targets for restoring the sensitivity of mutant cells to drug-induced cell death.

Materials and methods

Animals

The Kras\(^{G12D}\), p53\(^{lox/lox}\), and TPO-Cre strains have been described previously (Jonkers et al. 2001, Kusakabe et al. 2004, Tuveson et al. 2004). All strains were backcrossed in the 129Sv background for at least ten generations, and littermates were used as controls.

Hormone measurements

Blood was collected by cardiac puncture. Serum thyroid-stimulating hormone (TSH) was measured using a sensitive, heterologous, disequilibrium double-antibody precipitation RIA (Pohlenz et al. 1999), and results were expressed in mU/l. All samples were individually analyzed for each mouse. Total thyroxine (T\(_4\)) concentrations were measured by a solid-phase RIA (Coat-a-Count; Diagnostic Products Corp., Los Angeles, CA, USA) adapted for mice. The values of the respective limits of assay sensitivities were assigned to samples with undetectable TSH or T\(_4\) concentrations.

Immunohistochemistry

Sections of 6 \(\mu\)m thickness were subjected to antigen retrieval, incubated with antibodies against thyroglobulin and Ki67 (Dako, Carpinteria, CA, USA), or vimentin, E-cadherin, and pAKT-S473 (Cell Signaling, Danvers, MA, USA), and counterstained with hematoxylin.

Establishment and maintenance of cell lines

Primary thyroid tumors were minced and resuspended in Ham’s F12/10% FBS with 100 U/ml type 1 collagenase (Sigma) and 1 U/ml dispase (Roche). Enzymatic digestion was carried out for 60 min at 37 °C. After digestion, cells were seeded in Ham’s F12 containing 40% Nu-Serum IV (Collaborative Biomedical, Bedford, MA, USA), gly–his–lys (10 ng/ml, Sigma), and somatostatin (10 ng/ml, Sigma) and allowed to spread and reach confluence before being passaged. After the fourth passage, tumor cells were adapted to grow in DMEM/10%FBS. Cal62 cells were grown in RPMI/10%FBS. Identity was validated by amplifying and sequencing genomic fragments encompassing their known mutation (KRAS G12R).

Metaphase preparation and chromosome analysis

For chromosome preparation, primary cells at passage p1–p4 were plated in a 35 mm Petri dish and incubated with Colcemid (Sigma–Aldrich) at a concentration of 10 ng/ml overnight or for 3 h at 100 ng/ml. Chromosomes were extracted with standard hypotonic treatment (0.075 M KCl), dropped on microscope slides, and mounted with antifade containing DAPI (Invitrogen). Slides were imaged on a Zeiss Axiovert 200 Microscope using a DAPI filter (Chroma Technologies, Bellows Falls, VT, USA). Ten fields were selected randomly and 15–30 cells for each tumor line were subjected to chromosome counts and visually inspected for the presence of gross chromosome abnormalities and chromosome fragments.

Real-time PCR

Total RNA was extracted with Trizol and reverse transcribed using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). qRT-PCR was performed on a StepOne Plus apparatus using the Absolute
Blue qPCR Rox Mix (Thermo) and TaqMan expression assays (Applied Biosystems) or the SYBR Green mix (Applied Biosystems) and custom-designed primers (sequences available upon request). Each sample was run in triplicate and 18S was used to control for input RNA. Data analysis was based on the threshold cycle (Ct) method, and experiments were repeated at least three times using at least two independent organ pools (at least five mice/pool).

Western blot analysis

Cells were homogenized on ice in RIPA buffer supplemented with Complete protease inhibitor tablets (Roche Diagnostics). Western blot analysis was performed on 20–40 μg proteins using phospho-antibodies obtained from Cell Signaling.

Antibody arrays

The Proteome Profiler Human Phospho-Kinase Antibody Array (#ARY003B R&D System, Minneapolis, MN, USA) was probed with extracts from control and GSK1120212-treated cells according to the manufacturer’s instructions.

Drug treatments, cell viability, and cell proliferation analysis

GSK1120212 and Obatoclax (Selleck Chemicals, Houston, TX, USA) and doxorubicin (Sigma–Aldrich) were added 24 h after plating, in sexuplicate. After 48–72 h, viability was assessed using the Wst1 assay (Clontech) and IC_{50}s were determined using the Prism software. Alternatively, cells were trypsinized and counted using a Z2 Coulter counter (Beckman Coulter, Indianapolis, IN, USA).

Synergy analysis

Statistical analysis of drug synergy was evaluated from the results of the Wst1 assays and calculated using the Chou–Talalay method (Chou & Talalay 1984) and Compusyn software (www.combosyn.com). To determine synergy between two drugs, the software uses a median-effect method that determines whether the drug combination produces greater effects together than expected from the summation of their individual effects. The combination index (CI) values were calculated for the different dose–effect plots (for each of the serial dilutions) based on the parameters derived from the median-effect plots of the individual drugs or drug combinations at the fixed ratios. The CI was calculated based on the assumption of mutually nonexclusive drug interactions. CI values significantly greater than 1 are antagonistic, not significantly different from one are additive, and values less than 1 are synergistic.

Cell-cycle DNA analysis

Cells were seeded in 10 cm plates, cultured overnight at 37 °C, and incubated for 48 h with GSK1120212 or Obatoclax. Cells were harvested by trypsin treatment and fixed in 75% ethanol on ice. After treatment with RNase, cells were stained with propidium iodide overnight at 4 °C, and the DNA content was measured using a Becton Dickinson LSR II System (BD Biosciences, Franklin lakes, NJ, USA).

Annexin V staining

Cells were seeded in 10 cm plates, cultured overnight at 37 °C, and incubated for 48 h with GSK1120212 or Obatoclax. Cell culture supernatant was collected and added to the cells harvested by trypsin treatment. Cells were stained with Annexin V FITC and PI (BD Pharmigen, Franklin Lakes, NJ, USA) for 15 min at room temperature in the dark. Samples were analyzed by flow cytometry within 1 h using a Becton Dickinson LSR II System (BD Biosciences).

Allograft generation and treatment

WT female 129Sv mice that were 8–10 weeks old received injections of 6×10^6 D445 cells. When tumors reached a size between 100 and 250 mm^3, mice were randomized to placebo, GSK1120212 treatment (1 mg/kg), Obatoclax treatment (4 mg/kg), or combination treatment groups (n=7/group). GSK1120212 was administered via oral gavage, and Obatoclax via i.p. injection once every day, and the tumor volume was calculated from two-dimensional measurements using the following equation: tumor volume = (length×width^2)/2.

Expression profiling analysis

The dataset GSE27155 was downloaded from the GEO repository and analyzed using GenePattern (Reich et al. 2006).

Statistical analysis

Experiments were carried out at least three times. Data were analyzed using the Prism software package.
Differences with $P$ values <0.05 were considered statistically significant.

**Results**

**A novel mouse model of poorly differentiated thyroid cancer**

Mice carrying a thyroid-specific deletion of $p53$ and expressing the oncogenic $Kras^{G12D}$ allele in the thyroid epithelial cells had a median survival of 8.8 months and developed with full penetrance neoplastic lesions starting at 5 months of age (Fig. 1A). Double-mutant mice exhibited a slight decrease in the serum levels of TSH, but no significant alterations in T4 levels (Table 1). Postmortem analysis of tumor-bearing mice revealed very enlarged glands ($207.8 \pm 61$ vs $18 \pm 0.5$ mg in WT mice) often tightly adhering to nearby anatomical structures.

Histopathological analysis of the tumors developed by $Kras^{G12D}, p53^{ thyr}{1/1}$ mice indicated that they resemble follicular-cell-derived thyroid carcinomas in humans. Well-differentiated papillary thyroid carcinomas (PTCs) were most prevalent in younger mice and were characterized by papillae and follicle formations, the presence of colloid, low mitotic rate, and absent tumor necrosis (Fig. 1B). Poorly differentiated carcinomas (PDTCs) coexisted with PTCs, displayed organoid growth in the form of solid nests, papillae, or follicles, and exhibited tumor necrosis (often located in the center of the tumor nests) with increased mitotic activity (Fig. 1B). These tumors were often metastatic to the lungs (28% of cases) and displayed elevated staining for the proliferation marker Ki67 (Fig. 1C). Immunostaining for the differentiation marker thyroglobulin showed diffuse labeling in the PTC areas, while the stain labeled only focally the poorly differentiated component (Fig. 1C).

In 40% of mice (six out of 15), tumors contained areas of progression to anaplastic carcinoma, growing in sheets without any organoid formation, composed of markedly pleomorphic spindle or epithelioid cells with very high mitotic activity including atypical mitosis and large areas of tumor necrosis (Fig. 1D). Anaplastic carcinomas did not show any convincing specific staining for thyroglobulin (not shown).

To further characterize the progression from PTC to PDTC and anaplastic thyroid cancer (ATC), we performed

---

**Figure 1**

$Kras^{G12D}, p53^{ thyr}{1/1}$ mice develop papillary thyroid cancer progressing to poorly differentiated and anaplastic carcinomas. (A) Cumulative tumor incidence for mice of the indicated genotypes. (B) Low-magnification (40×) view of a representative tumor showing well-differentiated (PTC), poorly differentiated (PDTC), and anaplastic (ATC) components. The inset (200×) shows a nest of PDTC with adjacent tumor necrosis (asterisk).

(C) Top left, PDTC lung metastasis with central tumor necrosis and presence of organoid growth (100×); top right, Ki67 staining showing elevated proliferative index; bottom, immunostaining for thyroglobulin in PTC and PDTC components. (D) Contiguous PTC and ATC (100×); inset: PTC papillae (asterisk), mitotic figure (arrowhead), and anaplastic cells (arrow) (200×). All tumors are from 40- to 50-week-old mice.
immunohistochemistry for E-cadherin and vimentin, positive and negative markers of epithelial-to-mesenchymal transition (EMT) respectively. PDTC areas showed a moderate reduction in E-cadherin staining, and no increased vimentin expression, compared with the adjacent PTCs (Fig. 2). Conversely, ATCs showed complete loss of E-cadherin staining and dramatically increased vimentin expression, confirming that these more advanced tumors undergo EMT (Fig. 2). Furthermore, all three histological components (PTC, PDTC, and ATC) of these tumors showed no immunoreactivity for active AKT (pSer473), indicating that the PI3K pathway is not active in tumors driven by Kras activation and p53 loss (Fig. 2).

A frequent aspect of human PDTC and ATC is genomic instability, leading to aneuploidy (Wreesmann et al. 2002). We analyzed metaphase spreads from early-passage primary cultures of several tumors developed by KrasG12D p53+/− mice and found that these cultures contained a distinct aneuploid population (Supplementary Figure 1, see section on supplementary data given at the end of this article).

Human PDTC is generally characterized by preserved expression of the FOXE1, PAX8, and NKX2-1 transcription factors and the thyroid-specific genes TSHR, TPO, and TG. Expression of NIS (SLC5A5) is often reduced, leading to refractoriness to radioactive iodine therapy. Complete loss of thyrocyte differentiation is instead a hallmark of human ATC. We used real-time PCR to measure the expression levels of these genes associated with thyroid differentiation and function in freshly dissected glands and tumors. Expression of Foxe1, Pax8, and Nkx2-1, as well as the thyroid-specific genes Tshr, Tpo, and Tg, was generally not altered in single mutants, while the expression levels of Nis (Slc5a5) were increased in p53−/− glands and reduced in KrasG12D glands (Fig. 3A and B). PDTCs and ATCs retained expression of the thyroid-defining transcription factors and generally showed progressive (less expression with increasing ATC component) loss of Tpo, Tg, and Nis (Slc5a5) expression (Fig. 3A and B).

**MEK inhibition arrests cell growth without inducing cell death**

To aid in the molecular and preclinical characterization of the tumors developed by KrasG12D p53thy−/− mice, we have established several cell lines from lesions of different prevailing histologies: two of these lines, D316 (PDTC/ATC original tumor) and D445 (PTC/PDTC original tumor), have been used in the experiments described below.

The notion that activation of Kras is the driver oncogenic event for thyrocyte transformation in this model leads to the question of whether these tumors are sensitive to the inhibition of MEK1 and MEK2. We used

### Table 1 Hormonal status of control and mutant mice

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>KrasG12D p53−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (mU/l)</td>
<td>336.5 ± 31.5</td>
<td>166.7 ± 46.8</td>
</tr>
<tr>
<td>T₄ (μg/dl)</td>
<td>2.40 ± 0.39</td>
<td>2.94 ± 0.36</td>
</tr>
</tbody>
</table>

*Figure 2*

Immunohistochemical detection of E-cadherin, vimentin, and pAKT in PTC, PDTC, and ATC components of the same tumor. Note the progressive loss of E-cadherin, acquisition of vimentin, and absence of activated AKT.
two cell lines derived from our mouse model, as well as a human ATC cell line, Cal62, which harbors the same genetic alterations and thus represents an appropriate human counterpart to the mouse lines. These cell lines were treated with the specific MEK1/2 inhibitor GSK1120212 for 72 h to establish a dose–response curve. Although the presence of a significant tetraploid component in the mouse cell lines partially masked this effect (because the G1-arrested tetraploid cells overlap the diploid G2 peak), G1 arrest was also apparent in both D316 and D445 (Fig. 4B).

Growth inhibition was associated with robust cell cycle arrest in the G1 phase in Cal62 cells (Fig. 4B). Although the presence of a significant tetraploid component in the mouse cell lines partially masked this effect (because the G1-arrested tetraploid cells overlap the diploid G2 peak), G1 arrest was also apparent in both D316 and D445 (Fig. 4B).

Importantly, both direct cell counting over several days (not shown) and Annexin V staining of GSK1120212-treated cells showed complete absence of any apoptotic response upon inhibition of the MEK/MAPK pathway in both mouse and human Kras\(^{G12D,p53^{−/−}}\) cells (Fig. 4C).

We thus tested whether MEK inhibition might result in the activation of feedback loops restoring MAPK phosphorylation or activating compensatory PI3K-mediated pathways in order to support survival in the face of MEK inhibition. Time course analysis of mouse and human cells treated with 100 nM GSK1120212 for up to 48 h did not reveal any restoration of phosphorylated ERK1/2, and no activation of AKT was detectable at any time point (Fig. 4D). We also used an antibody array to interrogate on a larger scale the changes in the phosphokinome of both D316 and Cal62 cells upon GSK1120212 treatment. Besides the expected inactivation of ERK1/2, no significant and consistent GSK1120212-induced changes were detected in either cell lines (Fig. 4E and data not shown). These data strongly indicate that resistance to apoptosis upon inhibition of MEK/MAPK is an intrinsic trait of Kras\(^{G12D,p53^{−/−}}\) cells and not an adaptive response to MEK inhibition.

**Kras\(^{mut}\)** thyroid tumors overexpress *Bcl2a1* and *Mcl1*

We proposed the hypothesis that the intrinsic resistance to cell death might be associated with altered levels of pro- and anti-apoptotic members of the Bcl2 family. Thus, we measured the expression levels of eight pro-apoptotic and five anti-apoptotic genes in normal thyroid and primary thyroid tumors from Kras\(^{G12D,p53^{−/−}}\) mice. As shown in Fig. 5, thyroid tumors with varying predominance of the three histological components (PTC, PDTC, and ATC) displayed significantly (at least twofold) elevated mRNA levels for *Bax, Bak* (Bak1), *Bid, Bim* (Bcl2l11), *Noxa* (*Pmaip1*), and *Puma* (*Bbc3*), indicating that these tumors are in fact primed to undergo apoptosis. The same trend was observed at the protein level (Fig. 5C). Strikingly, at the same time, these tumors also showed substantial upregulation, both at the RNA and protein levels, of two potent anti-apoptotic genes, *Bcl2a1* and *Mcl1*.
A Bcl2 family inhibitor restores cell death response in \textit{Kras}^{mut} tumors

To test whether the high levels of \textit{Bcl2a1} and \textit{Mcl1} protect \textit{Kras}^{G12D, p53<sup>−/−</sup>} cells from apoptosis, we used two BH3 mimetic inhibitors, ABT-263 (Tse \textit{et al.} 2008) and Obatoclax (Nguyen \textit{et al.} 2007). ABT-263 targets \textit{Bcl2}, \textit{Bclxl}, and \textit{Bclw}, but not \textit{Bcl2a1} or \textit{Mcl1}, while Obatoclax targets all anti-apoptotic members of the Bcl2 family. ABT-263 was modestly effective in reducing cell viability, while Obatoclax efficiently inhibited cell proliferation in all the three \textit{Kras}^{G12D, p53<sup>−/−</sup>} cell lines tested (Fig. 6A), with IC<sub>50</sub>s in the low nanomolar range. While at lower doses, Obatoclax induced, as shown previously in other cells (Urtishak \textit{et al.} 2013), an accumulation of cells in S-phase without evidence of cell death (Fig. 6B and C), treatment with 500 nM Obatoclax for 48 h induced massive cell death (Fig. 6C). Thus, \textit{Kras}^{G12D, p53<sup>−/−</sup>} cells are effectively killed by BH3 mimetics that specifically bind to and inhibit \textit{Bcl2a1} and \textit{Mcl1}.

Then, we tested whether Obatoclax would synergize with inhibition of the RAS/MEK/ERK signaling cascade, which drives these tumors. We compared the single-agent dose–response curves in the mouse cell lines with the curve obtained using the two drugs combined at a fixed
ratio based on the most effective single-dose concentration for each drug. The combination treatment was more effective than each single agent over a wide range of concentrations (Fig. 6D). In order to establish whether the combined effects of GSK1120212 and Obatoclax were synergistic rather than additive, we calculated the CI according to the well-established Chou and Talalay median-effect method (Chou & Talalay 1984). The CI for the ED95 indicated clearly synergistic effects (CI = 0.47).

In order to define the molecular basis for the synergy between MEK1/2 and Bcl2 family inhibition, we determined the changes in expression levels of pro- and anti-apoptotic molecules upon exposure to the inhibitors. GSK1120212 and Obatoclax treatment, alone and in combination, increased the levels of several pro-apoptotic Bcl2 family members (Bax, Noxa, and Bim), thus predisposing the tumor cells to death (Fig. 6E). At the same time, GSK1120212 strongly reduced the expression of Bcl2a1, alone and in combination with Obatoclax (Fig. 6F). On the other hand, Obatoclax, as a single agent, increased the expression of most anti-apoptotic Bcl2 family members, probably through a compensatory feedback mechanism. Thus, the synergy between the two compounds is probably obtained through simultaneous upregulation of pro-apoptotic genes, and downregulation and inhibition of anti-apoptotic genes.

The ability of Obatoclax to induce cell death in therapy-resistant cells prompted us to test whether inhibition of Bcl2a1 and Mcl1 would sensitize these cells to doxorubicin treatment, which is a current, although poorly effective, standard in advanced thyroid cancer chemotherapy (Shimaoka et al. 1985). Indeed, both mouse and human KrasG12D, p53−/− cell lines exhibited significantly increased cell death when treated with a combination of GSK1120212 and Obatoclax, than when treated with each compound alone (Fig. 7).

Finally, we used an immunocompetent in vivo system, i.e. 129Sv mice bearing D445 allograft tumors, to test the efficacy of Obatoclax as a sensitizer to cell death. Strikingly, the combination of Obatoclax (4 mg/kg) and GSK1120212 (1 mg/kg) resulted in a significant degree of tumor control compared with each drug alone (Fig. 8).

**Dysregulation of Bcl2 family members is a feature of human aggressive thyroid carcinomas**

We used a large expression-profiling dataset (99 samples) available from the GEO repository (Giordano et al. 2005) to test whether the dysregulation of the expression levels of Bcl2 family members observed in our mouse model recapitulates specific human thyroid cancer subtypes. Strikingly, overexpression of MCL1, BCLXL (BCL2L1), and BID, and downregulation of BCL2, BAD, and BIK (as observed in the PTCs, PDTCs, and ATCs developed by KrasG12D, p53−/− mice) were able to separate classical papillary, tall-cell-variant papillary, and anaplastic carcinomas from all the other subtypes present in the dataset. Additional upregulation of BCL2A1 and NOXA identified a smaller subset of thyroid carcinomas that included all the anaplastic tumors present in the dataset. These results strongly indicate that dysregulation of a set of Bcl2 family
Figure 6
Obatoclax induces cell death in Kras<sup>G12D,p53<sup>thyr</sup>-/-</sup> cells and synergizes with MEK inhibition. (A) Effect of ABT-263 and Obatoclax on the viability of tumor cells. (B) Flow cytometric cell cycle analysis of D316 cells treated with 100 and 500 nM Obatoclax. (C) Annexin V staining showing extensive cell death upon treatment of D316 cells with 500 nM Obatoclax. Experiments were replicated with similar results in D445 cells. (D) Dose–response curves showing the cooperative effect of a GSK11201212/Obatoclax combination on the viability of the mouse cell line D445. Drugs were combined at a fixed ratio of 1:5 (GSK/Oba). CI<sub>E95</sub>: combination index at a drug dose causing 95% reduction in viability. Experiments were replicated with similar results in D316 cells. (E and F) qPCR analysis of the expression of pro- and anti-apoptotic Bcl2 family members in D316 cells upon 6 h treatment with Obatoclax, GSK11201212, and both in combination. Experiments were replicated with similar results in D445 cells.
members, including \textit{MCL1} and \textit{BCL2A1}, identifies thyroid carcinomas with particularly aggressive features (Fig. 9).

**Discussion**

As for other tumor types, genetically defined murine models of thyroid cancer are invaluable tools to dissect the molecular pathways and events leading to neoplastic transformation and tumor progression, and to test novel, targeted therapeutic approaches in a physiological, immunocompetent system. The past few years have thus seen the generation and exploitation of highly relevant mouse models for follicular (Suzuki et al. 2002, Antico-Arciuch et al. 2010, Pringle et al. 2014), papillary (Jhiang et al. 1996, Knauf et al. 2005, Chakravarty et al. 2011), and ATC (Antico Arciuch et al. 2011, Charles et al. 2014, McFadden et al. 2014). Areas of poor differentiation were observed in advanced papillary tumors developed by \textit{BRAF} \textit{V600E} mice (Knauf et al. 2011). Herein, we report the generation and characterization of a \textit{RAS}-driven model that shows progression from papillary lesions to PDTC and, in several cases, to ATC. This model faithfully recapitulates human PDTC, both in terms of morphological and immunohistochemical features, and in terms of genomic instability and tumor aggressiveness. As such, this model represents a valuable tool for identifying key signaling nodes that may allow therapeutic exploitation.

As expected for a model driven by activation of the RAS/\textit{MEK}/\textit{ERK} cascade, a MEK inhibitor was able to interfere with tumor cell proliferation. Interestingly, such inhibition was not accompanied by any of the compensatory feedback responses that have been observed in other systems and that can reactivate signaling and proliferation, in particular in \textit{KRAS} mutant tumors (Yoon et al. 2010, Turke et al. 2012, Carlino et al. 2014). However, despite prolonged inhibition of MAPK activity and arrest in G1 phase, tumor cells derived from our mouse model did not undergo cell death, indicating that this system is inherently resistant to apoptosis, similar to the situation observed in human aggressive thyroid tumors, for which cytotoxic therapy often fails. Our data show that the inability to undergo apoptosis, in spite of high levels of expression of pro-apoptotic effectors (Bak, Bid, Noxa, and \textit{Puma}), is at least in part associated with the elevated expression levels of two anti-apoptotic members of the \textit{Bcl2} family, \textit{Bcl2a1} and \textit{Mcl1}. \textit{BCL2A1} has been recently described as an oncogene responsible for hematopoietic stem cell transformation (Metais et al. 2012) and for resistance to \textit{BRAF} inhibition in melanoma (Haq et al. 2013). The role of \textit{MCL1} in cancer is well established (Ertel et al. 2013), and elevated levels of \textit{MCL1} have been reported to correlate with dedifferentiation in thyroid cancer (Branet et al. 1996). Accordingly, the pan-\textit{Bcl} family inhibitor Obatoclax, but not the more restricted inhibitor ABT-263, which does not target \textit{Bcl2a1} and \textit{Mcl1}, was able to induce tumor cell death even as a single agent, and to cooperate with MEK inhibition both in cultured
cells and, in vivo, in tumor cell allografts, as well as with doxorubicin treatment. Thus, targeted inhibition of anti-apoptotic proteins appears to be a valid strategy to sensitize otherwise resistant thyroid cancer cells to cell death induced by inhibition of the driver pathway or cytotoxic chemotherapy. In view of the possible ability of Obatoclax to induce different modes of cell death, including apoptosis, necroptosis, and autophagic death (Heidari et al. 2010, Basit et al. 2013, Urtishak et al. 2013, Yu & Liu 2013), future studies are required to dissect in depth the specific route through which RAS-mutant thyroid cells undergo cell death upon inhibition of anti-apoptotic Bcl2 family members, so that additional fine tuning of the death-inducing system can be achieved for optimal therapeutic responses.

Finally, we have shown that human thyroid cancer subtypes cluster in two main groups based on the expression of BCL2 family members: follicular, follicular variant, and oncocytic carcinomas express high levels of BCL2 and BCLW (BCL2L2), and thus may benefit from the sensitizing action of inhibitors such as ABT-263. Classic papillary, as well as the more aggressive tall-cell and anaplastic carcinomas, overexpress MCL1, BCLXL, and BCL2A1, and thus are more sensitive to the inhibitory activity of Obatoclax and its derivatives.

Thus, using a novel mouse model of progression from PTC to PDTC and ATC, as well as a genetically corresponding human cell line, we have uncovered a novel strategy to target thyroid cancer cells for death.

Figure 9
Heat map showing that different subtypes of human thyroid cancer cluster together based on the expression of BCL2 family members. Genes in green are downregulated and genes in red are upregulated in the mouse model. The red bar below the heat map indicates tumors overexpressing MCL1, and the blue bar indicates tumors overexpressing both MCL1 and BCL2A1, as in the mouse model.


Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene **30** 3153–3162. (doi:10.1038/ncg.2011.44)


**Bcl2 family targeting in thyroid cancer**

**21**:5 766

---

**Endocrine-Related Cancer**

**D Champa et al.**

**2014 Society for Endocrinology**

**Printed in Great Britain**

http://erc.endocrinology-journals.org

DOI: 10.1530/ERC-14-0268

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 07/05/2019 08:28:40PM via free access


Received in final form 7 July 2014
Accepted 9 July 2014
Made available online as an Accepted Preprint 10 July 2014